Uncategorized

Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost clear skin with Lilly’s lebrikizumab monthly maintenance dosing at two years

Patients with moderate-to-severe atopic dermatitis who continued treatment with investigational lebrikizumab for up to two years experienced sustained skin clearance, itch relief and reduced disease severity with monthly maintenance dosing as demonstrated in the ADjoin long-term extension study from Eli Lilly and Company.

Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost clear skin with Lilly’s lebrikizumab monthly maintenance dosing at two years Read More »

Bioretec Ltd’s Board of Directors has decided on a new option program 2023-1

The Board of Directors of Bioretec Ltd has on 20 October 2023 decided, on the basis of the authorization received from the company’s Annual General Meeting on 26 May 2023, to establish a new option program as an incentive scheme for the employees and consultants and members of the company’s Key Opinion Leader group of

Bioretec Ltd’s Board of Directors has decided on a new option program 2023-1 Read More »

Meilleur Technologies Inc. Announces Use of the Next-Generation Amyloid PET Imaging Biomarker, NAV-4694, in the Alzheimer’s Disease Neuroimaging Initiative 4 (ADNI4)

Meilleur Technologies, Inc. announced a research collaboration agreement with the Alzheimer’s Disease Neuroimaging Initiative 4, ADNI4, on the use of Meilleur’s [F-18]NAV-4694, an investigational imaging agent, in Positron Emission Tomography scans to assess the status amyloid plaque in the brain.

Meilleur Technologies Inc. Announces Use of the Next-Generation Amyloid PET Imaging Biomarker, NAV-4694, in the Alzheimer’s Disease Neuroimaging Initiative 4 (ADNI4) Read More »

Scroll to Top